IJARSCT

IJARSCT
ISSN: 2581-9429

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

Volume 6, Issue 2, July 2026

Impact Factor: 8.2

Artificial Intelligence-Assisted Design of Nanocarriers for Targeted Drug Delivery: Recent Advances, Challenges, and Future Perspectives

Kavita Gurjar, Gourav Chouhan, Sahil Basor, Abhishek, Vishnu Ojha
Aryabhatta College of Pharmacy, Ajmer, Rajasthan
Ojhavishnu8882@gmail.com

Abstract: *Targeted drug delivery has emerged as a transformative approach in modern therapeutics, enabling precise delivery of pharmaceutical agents to diseased tissues while minimizing systemic toxicity. Nanocarriers such as liposomes, polymeric nanoparticles, dendrimers, micelles, and inorganic nanoparticles have demonstrated significant potential in improving drug bioavailability and therapeutic efficacy. However, the design and optimization of nanocarriers remain complex due to the intricate relationships among physicochemical properties, biological interactions, and clinical outcomes. Artificial Intelligence (AI), encompassing Machine Learning (ML), Deep Learning (DL), and data-driven predictive analytics, has emerged as a powerful tool for accelerating nanocarrier development. AI facilitates rapid prediction of nanoparticle characteristics, optimization of formulations, identification of suitable drug candidates, and personalization of treatment strategies. This review explores the integration of AI technologies in nanocarrier design for targeted drug delivery, highlighting recent advances, applications, challenges, and future prospects. The review emphasizes how AI-driven approaches can revolutionize nanomedicine by enhancing precision, reducing development costs, and accelerating clinical translation.*

Keywords: Artificial Intelligence, Machine Learning, Nanocarriers, Targeted Drug Delivery, Nanomedicine, Deep Learning, Precision Medicine

I. INTRODUCTION

Drug delivery systems play a critical role in determining the therapeutic effectiveness of pharmaceutical compounds. Conventional drug administration methods often suffer from poor bioavailability, rapid degradation, non-specific distribution, and adverse side effects. Targeted drug delivery systems address these limitations by directing therapeutic agents specifically to diseased tissues. Nanocarriers have gained considerable attention due to their unique physicochemical properties, including high surface area, tunable size, controlled drug release, and surface functionalization capabilities. Despite significant progress, the rational design of nanocarriers remains challenging because multiple variables influence their performance. Artificial Intelligence has transformed several scientific disciplines by enabling data-driven decision-making and predictive modeling. In pharmaceutical sciences, AI offers unprecedented opportunities to optimize nanocarrier design, predict biological behavior, and accelerate drug development processes.

II. OVERVIEW OF NANOCARRIERS IN TARGETED DRUG DELIVERY

Nanocarriers are nanoscale delivery vehicles designed to transport therapeutic agents to specific sites within the body.

Types of Nanocarriers

Liposomes : Liposomes are phospholipid vesicles capable of encapsulating both hydrophilic and hydrophobic drugs.

Advantages:

- Biocompatibility

- Reduced toxicity
- Enhanced circulation time

Polymeric Nanoparticles
Prepared using biodegradable polymers such as PLGA and chitosan.
Applications:
- Controlled drug release
- Cancer therapy
- Gene delivery

Dendrimers
Highly branched macromolecules offering
- High drug loading capacity
- Surface modification flexibility
- Targeted delivery capability

Solid Lipid Nanoparticles Provide:
- Improved stability
- Controlled release
- Reduced toxicity

Inorganic Nanoparticles Examples include:
- Gold nanoparticles
- Silica nanoparticles
- Magnetic nanoparticles

Applications:
- Imaging
- Drug delivery
- Theranostics

III. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL RESEARCH
AI refers to computational systems capable of performing tasks requiring human intelligence.
3.1 Machine Learning
Machine learning algorithms learn patterns from data and generate predictive models.
Common algorithms include:
- Random Forest
- Support Vector Machines
- Decision Trees
- K-Nearest Neighbors

Applications:
- Drug discovery
- Toxicity prediction
- Formulation optimization

3.2 Deep Learning
Deep learning utilizes multilayer neural networks for complex pattern recognition.
Examples:
- Convolutional Neural Networks (CNNs)
- Recurrent Neural Networks (RNNs)

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, July 2026
Impact Factor: 8.2

- Graph Neural Networks (GNNs)

Applications:

- Molecular property prediction
- Image analysis
- Nanoparticle characterization

3.3 Reinforcement Learning

Reinforcement learning enables optimization through reward-based learning mechanisms.

Applications:

- Molecular design
- Drug candidate optimization
- Nanocarrier formulation development

IV. RESEARCH OBJECTIVES

i. To provide an overview of nanocarrier-based targeted drug delivery systems, including liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, and inorganic nanocarriers.

ii. To examine the fundamental concepts of Artificial Intelligence, Machine Learning, and Deep Learning relevant to pharmaceutical and nanomedicine research.

iii.To analyze the application of AI in nanocarrier design and formulation development, including prediction of particle size, drug loading, encapsulation efficiency, stability, and release kinetics.

iv.To evaluate AI-based approaches for predicting biological interactions such as cellular uptake, bio distribution, protein corona formation, and nanotoxicity.

V. APPLICATIONS IN CANCER TARGETED THERAPY

Cancer remains one of the leading causes of mortality worldwide.

AI-assisted nanocarriers improve:

- Tumor targeting
- Drug accumulation
- Therapeutic efficacy
- Examples include:

AI-Optimized Liposomal Formulations

Used for:

- Doxorubicin delivery
- Reduced cardiotoxicity
- Enhanced tumor penetration
- Smart Nanoparticles

Stimuli-responsive systems activated by:

- pH changes
- Temperature
- Enzymatic activity

AI predicts optimal design parameters

VI. RESULTS & DISCUSSION

The integration of Artificial Intelligence into nanocarrier design has significantly improved the efficiency of targeted drug delivery research. Machine learning models demonstrate high predictive accuracy in forecasting nanoparticle size, drug loading efficiency, and release kinetics. Deep learning approaches have shown superior performance in analyzing complex biological datasets and predicting nanoparticle-cell interactions. AI-assisted formulation optimization reduces experimental workload by identifying optimal formulation parameters with fewer laboratory trials. In cancer therapy, AI-driven nanocarriers have improved tumor targeting, reduced systemic toxicity, and enhanced therapeutic outcomes. Furthermore, predictive toxicity assessment using AI minimizes safety risks and accelerates preclinical development. Despite challenges related to data availability and model interpretability, emerging explainable AI techniques are expected to address these concerns. Overall, AI-assisted nanocarrier development represents a paradigm shift toward intelligent, data-driven, and personalized drug delivery systems.

VII. CONCLUSION

Artificial Intelligence has emerged as a transformative technology in the design and optimization of nanocarriers for targeted drug delivery. By integrating machine learning, deep learning, and predictive analytics, researchers can accelerate formulation development, improve targeting efficiency, reduce toxicity, and support personalized medicine approaches. While challenges remain regarding data quality, interpretability, and regulatory acceptance, continuous advancements in AI methodologies are expected to drive the next generation of smart nanomedicine. The convergence of AI and nanotechnology promises to revolutionize healthcare by enabling safer, more effective, and patient-specific therapeutic interventions.

REFERENCES

1. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy.
2. Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery.
3. Jain KK. Nanomedicine: Application of nanobiotechnology in medical practice.
4. LeCun Y, Bengio Y, Hinton G. Deep learning.
5. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare.
6. Mamoshina P, Vieira A, Putin E, Zhavoronkov A. Applications of deep learning in biomedicine.
7. Agatonovic-Kustrin S, Beresford R. Basic concepts of artificial neural network modeling.
8. Liu Z, Jiang W, Nam J, et al. Nanoparticle interactions with biological systems.
9. He H, Liu L, Morin EE, et al. Machine learning for nanomedicine.
10. Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: Therapeutic applications and developments.
11. Dubey D. et al. (2023). A Study Of Recycling And Waste Management Strategies for Mechanical Systems And Products With Legal Aspects, Indian Journal of Science and Research. Vol.3 Issue-3. 78-83
12. Pande S. et al. (2023). A Study Of Impact Of Green Infrastructure On Environment, Indian Journal of Science and Research. Vol.3 Issue-2, 70-73